Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) Gross Margin (2020 - 2025)

Historic Gross Margin for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to 70.74%.

  • Biofrontera's Gross Margin rose 248500.0% to 70.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 64.41%, marking a year-over-year decrease of 17100.0%. This contributed to the annual value of 50.14% for FY2024, which is 13400.0% up from last year.
  • Latest data reveals that Biofrontera reported Gross Margin of 70.74% as of Q3 2025, which was up 248500.0% from 70.74% recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Gross Margin ranged from a high of 112.8% in Q4 2023 and a low of 77.84% during Q2 2023
  • Over the past 5 years, Biofrontera's median Gross Margin value was 70.74% (recorded in 2025), while the average stood at 59.81%.
  • The largest annual percentage gain for Biofrontera's Gross Margin in the last 5 years was 1850700bps (2023), contrasted with its biggest fall of -1744300bps (2023).
  • Quarter analysis of 5 years shows Biofrontera's Gross Margin stood at 98.03% in 2021, then tumbled by -174bps to 72.27% in 2022, then soared by 256bps to 112.8% in 2023, then tumbled by -49bps to 58.03% in 2024, then rose by 22bps to 70.74% in 2025.
  • Its Gross Margin was 70.74% in Q3 2025, compared to 70.74% in Q2 2025 and 61.95% in Q1 2025.